Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.1%

Johnson & Johnson (NYSE:JNJGet Free Report)’s stock price was down 1.1% during mid-day trading on Wednesday . The stock traded as low as $155.92 and last traded at $155.99. Approximately 1,351,176 shares changed hands during trading, a decline of 81% from the average daily volume of 7,008,399 shares. The stock had previously closed at $157.73.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on JNJ shares. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Morgan Stanley cut their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $177.31.

Read Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Stock Down 2.1 %

The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The company has a market cap of $372.29 billion, a PE ratio of 11.30, a PEG ratio of 2.65 and a beta of 0.53. The firm has a fifty day simple moving average of $158.45 and a 200 day simple moving average of $156.51.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The business had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter in the previous year, the business earned $2.35 EPS. The company’s revenue for the quarter was down 9.7% on a year-over-year basis. Equities research analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently made changes to their positions in the business. Hibernia Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $37,000. Tower View Wealth Management LLC grew its stake in Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the last quarter. Keener Financial Planning LLC bought a new position in Johnson & Johnson during the 4th quarter worth $40,000. Finally, WFA Asset Management Corp grew its stake in Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after buying an additional 97 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.